Table 3.
EC50 or IC50 values of the multiple mutation XIP analogs against the ComR receptora
| Name | Sequence | EC50 or IC50 (μM)b | 95% CIc |
|---|---|---|---|
| XIP | GLDWWSL | 0.44 | 0.37 – 0.52 |
| XIP-W4AL7A (P29) | GLDAWSA | 15 | 12 – 19 |
| XIP-G1AD3AS6A (P30) | ALAWWAL | 8.9 | 5.9 – 13 |
| XIP-G1AD3AW4YS6A (P31) | ALAYWAL | 22 | 14 – 36 |
| XIP-G1AD3AW4AS6A (P32) | ALAAWAL | 10 | 6.6 – 15 |
| XIP-G1AD3AS6AL7A (P33) | ALAWWAA | 11 | 6.8 – 17 |
| XIP-G1AD3AW4AS6AL7A (P34) | ALAAWAA | > 50 |
a
See experimental section for details on reporter strain and methods. See supporting information for primary screening assay results and plots of antagonism dose response curves. All assays were performed in triplicate.
b
IC50 values determined by testing peptides over a range of concentrations.
c
95% confidence interval.